See every side of every news story
Published loading...Updated

Bank of America Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

Summary by defenseworld.net
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price hoisted by equities researchers at Bank of America from $99.00 to $103.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price target points to a potential upside of 50.92% from the stock’s previous close. Several other equities analysts have also issued reports on…

2 Articles

All
Left
Center
1
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

americanbankingnews.com broke the news in on Saturday, February 22, 2025.
Sources are mostly out of (0)